Abivax Receives FDA Agreement on Pediatric Development Plan with Obefazimod in IBD

The FDA agreed on the initial Pediatric Study Plan (iPSP) for the development of obefazimod in children aged 2 to 17 years with inflammatory bowel diseases (IBD)Abivax global Phase 3 clinical program (ABTECT program) with obefazimod for the …